S&P 500   4,324.82 (-1.93%)
DOW   33,978.98 (-1.12%)
QQQ   343.46 (-2.79%)
AAPL   158.38 (-2.00%)
MSFT   286.96 (-3.18%)
FB   300.28 (-2.73%)
GOOGL   2,553.42 (-2.40%)
AMZN   2,790.81 (-3.46%)
TSLA   913.63 (-1.76%)
NVDA   222.80 (-4.67%)
BABA   118.79 (-1.31%)
NIO   23.56 (-5.27%)
AMD   110.93 (-4.81%)
CGC   7.10 (-4.05%)
MU   80.62 (-2.81%)
GE   89.91 (-7.22%)
T   26.08 (-0.99%)
F   19.88 (-2.50%)
DIS   134.44 (-2.20%)
AMC   15.96 (-4.09%)
PFE   51.85 (+0.60%)
ACB   4.07 (-5.79%)
BA   200.43 (-1.85%)
S&P 500   4,324.82 (-1.93%)
DOW   33,978.98 (-1.12%)
QQQ   343.46 (-2.79%)
AAPL   158.38 (-2.00%)
MSFT   286.96 (-3.18%)
FB   300.28 (-2.73%)
GOOGL   2,553.42 (-2.40%)
AMZN   2,790.81 (-3.46%)
TSLA   913.63 (-1.76%)
NVDA   222.80 (-4.67%)
BABA   118.79 (-1.31%)
NIO   23.56 (-5.27%)
AMD   110.93 (-4.81%)
CGC   7.10 (-4.05%)
MU   80.62 (-2.81%)
GE   89.91 (-7.22%)
T   26.08 (-0.99%)
F   19.88 (-2.50%)
DIS   134.44 (-2.20%)
AMC   15.96 (-4.09%)
PFE   51.85 (+0.60%)
ACB   4.07 (-5.79%)
BA   200.43 (-1.85%)
S&P 500   4,324.82 (-1.93%)
DOW   33,978.98 (-1.12%)
QQQ   343.46 (-2.79%)
AAPL   158.38 (-2.00%)
MSFT   286.96 (-3.18%)
FB   300.28 (-2.73%)
GOOGL   2,553.42 (-2.40%)
AMZN   2,790.81 (-3.46%)
TSLA   913.63 (-1.76%)
NVDA   222.80 (-4.67%)
BABA   118.79 (-1.31%)
NIO   23.56 (-5.27%)
AMD   110.93 (-4.81%)
CGC   7.10 (-4.05%)
MU   80.62 (-2.81%)
GE   89.91 (-7.22%)
T   26.08 (-0.99%)
F   19.88 (-2.50%)
DIS   134.44 (-2.20%)
AMC   15.96 (-4.09%)
PFE   51.85 (+0.60%)
ACB   4.07 (-5.79%)
BA   200.43 (-1.85%)
S&P 500   4,324.82 (-1.93%)
DOW   33,978.98 (-1.12%)
QQQ   343.46 (-2.79%)
AAPL   158.38 (-2.00%)
MSFT   286.96 (-3.18%)
FB   300.28 (-2.73%)
GOOGL   2,553.42 (-2.40%)
AMZN   2,790.81 (-3.46%)
TSLA   913.63 (-1.76%)
NVDA   222.80 (-4.67%)
BABA   118.79 (-1.31%)
NIO   23.56 (-5.27%)
AMD   110.93 (-4.81%)
CGC   7.10 (-4.05%)
MU   80.62 (-2.81%)
GE   89.91 (-7.22%)
T   26.08 (-0.99%)
F   19.88 (-2.50%)
DIS   134.44 (-2.20%)
AMC   15.96 (-4.09%)
PFE   51.85 (+0.60%)
ACB   4.07 (-5.79%)
BA   200.43 (-1.85%)
NASDAQ:MEIP

MEI Pharma Stock Forecast, Price & News

$2.24
-0.02 (-0.88%)
(As of 01/25/2022 11:34 AM ET)
Add
Compare
Today's Range
$2.21
$2.26
50-Day Range
$2.18
$3.37
52-Week Range
$2.05
$4.57
Volume
11,802 shs
Average Volume
776,756 shs
Market Capitalization
$252.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.34
30 days | 90 days | 365 days | Advanced Chart
Receive MEIP News and Ratings via Email

Sign-up to receive the latest news and ratings for MEI Pharma and its competitors with MarketBeat's FREE daily newsletter.


MEI Pharma logo

About MEI Pharma

MEI Pharma, Inc. is a pharmaceutical company, which engages in the clinical development of therapies for cancer. Its drug candidates include Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Its pipeline also consists of ME-401, an oral PI3K delta inhibitor; Voruciclib, an oral CDK inhibitor; and ME-344, a mitochondrial inhibitor. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MEIP
Previous Symbol
NASDAQ:MSHL
Employees
51
Year Founded
N/A

Sales & Book Value

Annual Sales
$25.53 million
Book Value
$0.37 per share

Profitability

Net Income
$-50.58 million
Net Margins
-172.03%
Pretax Margin
-172.01%

Debt

Price-To-Earnings

Miscellaneous

Free Float
106,330,000
Market Cap
$252.50 million
Optionable
Optionable

Company Calendar

Last Earnings
11/10/2021
Today
1/25/2022
Next Earnings (Estimated)
2/03/2022
Fiscal Year End
6/30/2022

MarketRank

Overall MarketRank

2.09 out of 5 stars

Medical Sector

534th out of 1,415 stocks

Pharmaceutical Preparations Industry

249th out of 683 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












MEI Pharma (NASDAQ:MEIP) Frequently Asked Questions

Is MEI Pharma a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MEI Pharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MEI Pharma stock.
View analyst ratings for MEI Pharma
or view top-rated stocks.

How has MEI Pharma's stock price been impacted by Coronavirus?

MEI Pharma's stock was trading at $1.55 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MEIP stock has increased by 44.5% and is now trading at $2.24.
View which stocks have been most impacted by COVID-19
.

Are investors shorting MEI Pharma?

MEI Pharma saw a decline in short interest in the month of December. As of December 15th, there was short interest totaling 6,990,000 shares, a decline of 20.1% from the November 30th total of 8,750,000 shares. Based on an average daily trading volume, of 1,470,000 shares, the days-to-cover ratio is presently 4.8 days. Approximately 6.5% of the company's stock are sold short.
View MEI Pharma's Short Interest
.

When is MEI Pharma's next earnings date?

MEI Pharma is scheduled to release its next quarterly earnings announcement on Thursday, February 3rd 2022.
View our earnings forecast for MEI Pharma
.

How were MEI Pharma's earnings last quarter?

MEI Pharma, Inc. (NASDAQ:MEIP) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.13) earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of ($0.13). The business had revenue of $13.39 million for the quarter, compared to analysts' expectations of $9.98 million. MEI Pharma had a negative net margin of 172.03% and a negative trailing twelve-month return on equity of 100.10%.
View MEI Pharma's earnings history
.

What price target have analysts set for MEIP?

4 analysts have issued 12 month price objectives for MEI Pharma's shares. Their forecasts range from $8.00 to $20.00. On average, they anticipate MEI Pharma's share price to reach $11.75 in the next year. This suggests a possible upside of 424.6% from the stock's current price.
View analysts' price targets for MEI Pharma
or view top-rated stocks among Wall Street analysts.

Who are MEI Pharma's key executives?

MEI Pharma's management team includes the following people:
  • Daniel P. Gold, President, Chief Executive Officer & Director
  • David M. Urso, Chief Operating Officer & General Counsel
  • Brian G. Drazba, Chief Financial Officer & Secretary
  • Richard G. Ghalie, Chief Medical Officer
  • Tina C. Beamon, Chief Compliance Officer

What other stocks do shareholders of MEI Pharma own?

What is MEI Pharma's stock symbol?

MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP."

How do I buy shares of MEI Pharma?

Shares of MEIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MEI Pharma's stock price today?

One share of MEIP stock can currently be purchased for approximately $2.24.

How much money does MEI Pharma make?

MEI Pharma has a market capitalization of $252.50 million and generates $25.53 million in revenue each year. The company earns $-50.58 million in net income (profit) each year or ($0.66) on an earnings per share basis.

How many employees does MEI Pharma have?

MEI Pharma employs 51 workers across the globe.

What is MEI Pharma's official website?

The official website for MEI Pharma is www.meipharma.com.

Where are MEI Pharma's headquarters?

MEI Pharma is headquartered at 11455 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130.

How can I contact MEI Pharma?

MEI Pharma's mailing address is 11455 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The company can be reached via phone at (858) 369-7100, via email at [email protected], or via fax at 302-655-5049.


This page was last updated on 1/25/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.